Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome: An NCDR Research to Practice Project
Clinical trials serve as the foundation for evidence-based cardiovascular practice, but maximize their value only if they address questions relevant to current practice. The recent IMPROVE-IT trial demonstrated that adding ezetimibe to simvastatin in patients with recent acute coronary syndrome (ACS) reduced cardiac events by 2% over 7 years, 1 with those of the IMPROVE-IT trial population. 1 Racial and ethnicity classifications were based on patient selfreporting. Practice variation rates were reported as medians and interquartile ranges (IQR).
Results | Between January 2013 and September 2014, 28 454 PINNACLE patients with ACS at 182 practices were identified. Of these, 10 228 (35.9%) met IMPROVE-IT criteria (Figure) , with modest variation between practices (median 34.5%; IQR, 25.6-42.9). Compared with IMPROVE-IT patients, PINNACLE patients were significantly older, more likely female, had markedly higher rates of peripheral arterial disease, heart failure, and hypertension, and had lower rates of secondary prevention medication use (Table) .
Discussion | Only one-third of current patients with ACS would have qualified for the IMPROVE-IT trial, with modest practice variation. Compared with the trial population, qualifying PINNACLE patients were older, sicker, and received less optimal secondary prevention therapies. Thus, it is unclear if the effect seen with simvastatin/ezetimibe use in the trial translates to current patients with ACS. One factor reducing the applicability of IMPROVE-IT to practice is its use of a moderate-intensity statin, which deviates from the current guideline recommendation to use highintensity statins in all eligible patients with ACS. 3 In fact, as adherence to current guidelines increases, fewer and fewer patients will meet IMPROVE-IT criteria in clinical practice. In addition, trial patients were younger and considerably healthier than corresponding PINNACLE patients. In the world of clinical practice, clinicians must increasingly balance advanced age, multimorbidity, and polypharmacy with their treatment decisions. For trials to best inform clinical care, recruiting populations that more closely reflect these realities will be crucial.
There are limitations to our study. Our data may not fully capture all medication use or contraindications, so statin and other medication use may be underreported. PINNACLE practices may differ from nonparticipating practices, potentially limiting generalizability. Finally, PINNACLE is limited to US cardiology practices, and cannot speak to how the IMPROVE-IT trial may impact non-US clinical settings.
Conclusions | We found that the IMPROVE-IT trial population was not closely reflective of current clinical practice, calling into question the applicability of ezetimibe/simvastatin use to current patients with ACS. Strategies to more closely align trials with real-world patient characteristics are needed.
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